IGF mitogenic signaling pathway is an attractive therapeutic target in breast cancer per se [80], since high IGF1R levels are associated with resistance to treatment with a monoclonal antibody (mAb) that selectively recognizes the extracellular domain of HER2 and is currently used in the treatment of ERBB2-overexpressing breast cancer [81,82]. This evidence concerns the gene IGF1R and breast cancer.